What are the segments in the peri-implantitis treatment market?

The market is segmented by type, end-user, and by region. Read More

Peri-Implantitis Treatment Market Size & Share, by Type {Surgical (Bone Regeneration, Open Flap Debridement, Implantoplasty), Non-Surgical (Mechanical Debridement, Laser Debridement, Antibiotics), Surface Decontamination (Chemical, Laser)}; End-user (Dental Clinics, Hospitals, Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 3922
Published Date: Mar 13, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Peri-Implantitis Treatment Landscape

Aetna Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Pfizer Inc.
Cadila Pharmaceuticals Limited
R N Laboratories Pvt Ltd
Neoss Limited
Basic Pharma Lifesciences Pvt Ltd
Dawood and Tanner
Prachi Pharmaceuticals Private Limited
Geistlich Pharma AG.
Healthy Life Pharma Private Limited.

Browse Key Market Insights with Data Illustration:

Peri-Implantitis Treatment Market Size, Growth Forecasts 2035

In the News

Neoss Limited announced the acquisition of Legend Life Tech, to establish Neoss China, a regional subsidiary of the global implant manufacturing company. Neoss Limited aims to expand its global presence in the Asia Pacific region.
Geistlich Pharma AG. acquired Meta Technologies S.r.l., along with the employees working for the company. Geistlich Pharma expanded its existing offering of oral regeneration specialists, with the acquisition of Meta Technologies S.r.l.

Frequently Asked Questions (FAQ)

Growing consumption of cigarettes and increasing awareness of oral care are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2035.

Lack of awareness regarding the disease and higher cost associated with peri-implantitis treatment is estimated to be the growth hindering factors for the market expansion.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Pfizer Inc., Cadila Pharmaceuticals Limited, R N Laboratories Pvt Ltd, Neoss Limited, Basic Pharma Lifesciences Pvt Ltd, Dawood and Tanner, Prachi Pharmaceuticals Private Limited, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, end-user, and by region.

The surgical segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Companies Dominating the Peri-Implantitis Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the peri-implantitis treatment market?

What would be the CAGR of peri-implantitis treatment market over the forecast period?

What are the challenges affecting the peri-implantitis treatment market growth?

Which region will provide more business opportunities for growth of peri-implantitis treatment market in future?

Who are the major players dominating the peri-implantitis treatment market?

How are the company profiles selected?

What are the segments in the peri-implantitis treatment market?

Which segment captures the largest market size in end-user segment in the peri-implantitis treatment market?